Skip to main content

Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis



Opioid use disorder (OUD) as a common drug use disorder can affect public health issues, including the COVID-19 pandemic, in which patients with OUD may have higher risk of infection and severe disease. This systematic review and meta-analysis was conducted to investigate the risk of COVID-19 and the associated hospitalization, intensive care unit (ICU) admission, and mortality in patients with OUD.

Materials and Methods

A comprehensive systematic search was performed on PubMed, Scopus, Embase, and Web of Science to find studies which compared the infection rate and outcomes of COVID-19 in OUD patients in comparison with the normal population. A random effects meta-analysis model was developed to estimate odd ratios (OR) and 95% confidence interval (CI) between the outcomes of COVID-19 and OUD.


Out of 2647 articles identified through the systematic search, eight were included in the systematic review and five in the meta-analysis. Among 73,345,758 participants with a mean age of 57.90 ± 13.4 years, 45.67% were male. The findings suggested no significant statistical relationship between COVID-19 infection and OUD (OR (95% CI): 1.18 (0.47–2.96), p-value: 0.73). Additionally, patients with OUD had higher rate of hospitalization (OR (95% CI) 5.98 (5.02–7.13), p-value<0.01), ICU admission (OR (95% CI): 3.47 (2.24–5.39), p-value<0.01), and mortality by COVID-19) OR (95% CI): 1.52(1.27–1.82), pvalue< 0.01).


The present findings suggested that OUD is a major risk factor for mortality and the need for hospitalization and ICU admission in patients with COVID-19. It is recommended that policymakers and healthcare providers adopt targeted methods to prevent and manage clinical outcomes and decrease the burden of COVID-19, especially in specific populations such as OUD patients.


In March 2020, the World Health Organization announced COVID-19 as a pandemic. A total of 462 million confirmed patients with COVID-19 and over 6 million deaths caused by the disease had been reported until March 2022 [1, 2]. Although respiratory depression seems to be the most serious complication of COVID-19 infection, other physical and mental disorders were observed in infected individuals, especially in cases with a high virus load, such as healthcare workers [3,4,5,6]. As a major threat to public health, the growing mortality and morbidity associated with COVID-19 require the evaluation of the risk factors for COVID-19-induced complications.

As a common drug use disorder, opioid use disorder (OUD) globally affects 40.5 million people and 510 cases per 100,000 [7]. Research suggests that OUD is a risk factor that exacerbates COVID-19 outcomes [8, 9]. The immunosuppressive effects exerted on respiratory and mental systems by the unhealthy use of opioids can increase the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cause COVID-19-associated hospitalization, prolonged Intensive Care Unit (ICU) stay, adverse events and death. Moreover, decreased lung capacity caused by COVID-19 can worsen the condition associated with opioid overdose [10, 11]. The discrepancy is observed among the results associated with complications of COVID-19, such as hospitalization, ICU admission, and mortality in the studies [12,13,14]. However, despite the research performed on the effects of drug abuse on COVID-19 complications, the relationships between COVID-19 and OUD have rarely been addressed in the literature [15, 16]. Acquiring information about the risks of COVID-19 outcomes associated with OUD can therefore help determine patient risk and introduce evidence-based actions to clinicians and policymakers.

The present systematic review and meta-analysis aimed at examining the influence of OUD on the risk of infection with COVID-19 in the early phases of the pandemic. Hospitalization, ICU admission, and mortality were also investigated in OUD patients with COVID-19 compared with non-OUD ones.


Inclusion criteria and search strategy

The present systematic review and meta-analysis was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17]. Two authors, EB and BB, independently searched online databases of PubMed, Embase, Web of Science, and SCOPUS for articles published from January 2020 to December 2021. Inclusion criteria were the observational studies that investigated the rate of COVID-19 infection (either by Polymerase Chain Reaction (PCR) or clinical diagnosis by the physician) or outcomes (COVID-19-related hospitalization, ICU admission due to COVID-19, and mortality from it) of OUD patients compared with the overall population or the studies with substance use disorder (SUD) which included opioids in the total SUD definition. Exclusion criteria were non-English publications, case series recruiting below twenty patients, case reports, review articles, editorials, conference abstracts, nonclinical studies, preprints, and non-peer-reviewed studies, in addition to studies that did not mention OUD in their total SUD. The keywords included were COVID-19, SARS-CoV-2, opioid, opioid use disorder, hospital admission, hospitalization, intensive care, death, mortality, and other related MeSH terms. Additional file 1: Table S1 presents a complete list of the keywords used in the search. Reference screening of the included articles was also performed for possible new included studies.

After eliminating duplicated articles, two authors, AHB and EB, independently screened the titles and abstracts of the articles based on the inclusion criteria. In case of disagreement, the full text of the articles was explored, and any discrepancy was resolved through discussion with BB. A study with the largest dataset was chosen to be included in the systematic review and meta-analysis from articles including the same or nearly the same clinical population.

Quality assessment

The quality of the included articles was evaluated using the New Castle Ottawa Scale (NOS) designed for observational studies [18]. A NOS score of at least 7 was considered high quality, 5–6 as moderate quality, and less than 5 as low quality. EB and BB independently assessed the quality, and any disagreement was resolved through discussion with a third author (AHB).

Data extraction

With high consensus levels (kappa coefficient > 0.8), reviewers (EB and BB) independently extracted data from the eligible studies. As independent authors, MF and AHB cross-checked the data extraction and employed a standardized coding protocol to collect data such as country, age, gender, title of study, authors, publication date, study setting, study design, methodology, study population, and rate of outcomes.

Statistical analysis

The meta‐analysis was performed using Stata software (Stata/MP 16.0, Stata Corp LLC, College Station, Texas, USA). Odds ratio (OR) along with a 95% confidence interval (CI) was used to perform random-effect meta-analysis (DerSimonian-Laird model) for the comparison of each outcome between OUD and non-OUD groups. Cochran’s Q and I2 statistics were used based on the random-effects models to determine heterogeneity among the studies. The heterogeneity (I2) was classified as mild (25–49%), moderate (50–74%), and high (> 75%) [19]. The funnel plot and statistical examinations of Egger's, Begg's, and "trim and fill" tests were also used to identify potential publication bias [20, 21]. Meta-regression for the quantitative variables, including sample size, NOS score, male percentage, and publication year was conducted in order to identify the source of heterogeneity. The corresponding bubble plots were also designed. Two-tailed p-value < 0.05 was set as the level of statistical significance.


Screening the search results and quality assessment

According to the selection process of the PRISMA flow diagram in Fig. 1, a total of 2,647 records were identified by searching the databases, which then decreased to 1,868 after removing duplicates. Among these, 1,782 were excluded by title/abstract screening, and 86 were assessed for eligibility based on their full texts. Several articles investigated the complications of total SUD and COVID-19 outcomes did not focus on OUD complications separately. The present study extracted all the data of all studies that investigated total SUD with the inclusion of OUD and analyzed them based on associations between OUD and COVID-19 complications, as reported in the manuscript. Namely, SUD consisted of opioids, drugs, and alcohol (ethanol and methanol) in most of the studies.

Fig. 1
figure 1

Flow diagram summarizing the selection of eligible studies based on the PRISMA guidelines

Finally, a total of eight articles were included in the systematic review [22,23,24,25,26,27,28,29], of which three did not report OUD-only outcomes separately and reported the outcomes of overall SUD patients [22,23,24]. Table 1 illustrates the detail and findings of the articles included in the systematic review. The majority of studies were conducted in the United States [22, 23, 25,26,27], while two were done in Iran [28, 29] and one in Spain [24]. Moreover, the diagnosis of OUD was defined based on the interview [26, 28, 29], or from previously collected registries [23, 27].

Table 1 Baseline characteristics of the included studies

Five studies were included in the meta-analyses [25,26,27,28,29], representing 73,345,758 participants, of whom 49,184 had OUD. The mean age of participants was 57.90 ± 13.4, years and 45.67% of them were male. Out of the five included articles, four reported associations between OUD and COVID-19, two reported data on hospitalization, two reported ICU admission data, and two compared mortalities of COVID-19 patients.

Out of the eight quality-assessed peer-reviewed articles included in the systematic review, seven were rated as high-quality [22, 24,25,26,27,28,29] and one as moderate-quality [23]. GRADE assessment indicated high certainty for estimating the primary outcome and crude hospitalization and moderate certainty for adjusted hospitalization and ICU admission. Adjusted ICU admission was rated as very low certainty. Failing to properly match the two study groups and the follow-up of shorter than 30 days significantly contributed to reductions in the quality. Additional file 1 Table S2 summarizes the results of assessing the quality of the included articles.

Outcomes of meta-analysis, sensitivity analysis, publication bias and meta-regression

The random-effects analysis of the study outcomes revealed no robust evidence of increased risks of COVID-19 infection in the patients with OUD compared with those without OUD (Fig. 2; OR (95% CI): 1.18 (0.47–2.96); p-value: 0.73). This was associated with high Heterogeneity (I2 = 96.5%) for this outcome.

Fig. 2
figure 2

Results of COVID-19 infection meta-analysis

The results of COVID-19 outcomes are illustrated in Fig. 3. The risk of hospitalization after infection with the disease was significantly higher in the patients with OUD than in those without OUD with no heterogeneity (Additional file 1: Figure S1, OR (95% CI): 5.98 (5.02–7.13); p-value < 0.01). In addition, the pooled OR in the two included articles suggested that OUD increased the risk of ICU admission by more than threefold (Additional file 1: Figure S2, OR (95% CI): 3.47 (2.24–5.39); p-value < 0.01). With regards to mortality, OUD patients had a significantly higher death rate than those without OUD (Additional file 1: Figure S3, OR (95% CI): 1.52 (1.27–1.82); p-value < 0.01) Heterogeneity was low (I2 = 0.0%) in hospitalization, ICU admission, and mortality in these models.

Fig. 3
figure 3

Summary of meta-analyses on COVID-19 outcomes

Sensitivity analysis showed no significant change in ORs except for omitting Wang et al. (30), which resulted in a statistically significant effect size for COVID-19 infection in favor of OUD patients (OR (95% CI): 0.77 (0.61–0.97); p-value: 0.02).

As there was a high heterogeneity in COVID-19 infection analysis, meta-regression was performed to identify its source. The analyzed variables included sample size, NOS score, publication year, and the male percentage. The sample size was shown to be the only source of heterogeneity, contributing to 100% of it (p-value < 0.001). All other variables did not show any significant contribution to the heterogeneity (Table 2). This represents that the high heterogeneity observed is due to the difference in the sample sizes of the studies. Bubble plots for all these outcomes are shown in Additional file 1: figures S4 and Additional file 1: fig. S5 and Additional file 1: fig. S5 and Additional file 1: fig. S6 and Additional file 1: fig. S7.

Table 2 Meta-regression results for the COVID-19 infection outcome

The funnel plot for COVID-19 infection in patients with OUD showed apparent asymmetry, but Egger's and Begg’s tests did not reveal any significant publication bias (p-value : 0.46 and p-value : 00, respectively) (Additional file 1: Figure S8).


Our study assessed the association between OUD and COVID-19 infection in addition to the disease’s complications, including hospitalization, ICU admission, and mortality. Despite the insignificant association between OUD and COVID-19 infection, there was a higher rate of hospitalization in patients with OUD, compared to non-OUD cases. Our meta-analysis reported higher ICU admission rates in these patients; also, mortality was higher in the patients with OUD compared to those without.

A large body of literature suggests the immunosuppressive effects of chronic OUD among people with long-term opioid use (≥ 90 days a year) are exerted through binding to μ-opioid receptors, modulating downstream cellular signal pathways, and impairing the function of virtually immune cells [30,31,32]. ICU stay has been prolonged, and risks of COVID-19-related hospitalization, respiratory depression, and death have been increased in the globally-growing population of patients with OUD and compromised immune systems.

The included articles showed no significant associations between OUD and COVID-19. Given the controversial effects of OUD on COVID-19, research suggests a higher risk of COVID-19 in patients with substance use disorder or OUD [33,34,35,36]. Although not shown in our analysis, there can be several contributing factors for this, including their immunosuppression status caused by opioids, behavioral and economic factors, and living in crowded and closed places. On the other hand, resistance to COVID-19 was reported in tea and tobacco consumers, as well as in patients with OUD [37, 38]. The observation that COVID-19 infection was not statistically different in OUD and non-OUD groups may also stem from the fact that OUD cases are unwilling to appear in the general population or gatherings.

The results of this study showed significant differences between OUD and non-OUD in the aspect of hospitalization, which was reported similarly in several previous studies [15, 36, 39]. Respiratory depression caused by OUD can increase the risk of COVID-19-induced hypoxemia and immunosuppression and subsequently raise vulnerability to COVID-19 outcomes in patients with OUD, which causes a higher hospitalization rate. Since higher male percentage, higher age, and higher frequency of chronic conditions were associated with worse COVID-19 outcomes, such as hospitalization, these may be contributing factors for the results observed in OUD patients [40]. However, the causal relationship between these should be further studied. As there has been higher hospitalization in OUD cases, practical challenges in urgent need for the hospitalization of patients with OUD should be considered by healthcare systems, including comorbidities such as older age, cancer, psychiatric disorders (and the effect of their medications), and chronic pain [41,42,43], in addition to a higher risk of end-organ damage [44, 45]. Higher ICU admission and mortality rates observed in patients with OUD can also have clinical implications, including focusing on monitoring during the hospitalization course. In addition, healthcare providers anticipate long-term treatments and invasive procedures such as intubation in these patients. The adverse effects of opioids on the respiratory system and the associated increased histamine release caused by OUD also cause extubating challenges in these patients [30,31,32, 46, 47]. Moreover, medications used preliminary for COVID-19, such as hydroxychloroquine and azithromycin, although the efficacy could not be later established in studies [48, 49], significantly interact with certain opioids, including methadone [50, 51]. Clinicians should be, therefore, aware of the co-prescription of drugs and medicines used for opioid withdrawal in inpatients.

This meta-analysis suggested associations between OUD and ICU admission after adjusting for other risk factors in the included articles, such as age, sex, race, COVID-19 medications, and some underlying conditions like cancer, hypertension, diabetes, immunosuppression, and asthma, which can be attributed to different comorbidities and complications in the individual patients. Given the controversial relationships between ICU admission and OUD [52,53,54], there may be the chance of low-quality study or wide range for OR which can affect the overall results and should be considered in future studies.

In line with the literature, the present research showed increased risks of COVID-19-associated mortality in patients with OUD, which can stem from biological processes such as immunosuppression and elevated cytokine concentration [22, 27, 55]. Saeedi et al. reported significant associations between OUD and mortality in patients with COVID-19 (OR (95% CI): 3.59, (0.9–14.5)) [34]. Furthermore, OUD was reported as a contributing factor to increasing several infectious diseases such as HIV, endocarditis, hepatitis, and some other viral infections [56].

The higher hospitalization, ICU admission, and mortality in OUD patients should be taken into consideration in the vaccination programs. These programs have been implemented globally, and the efficacy of vaccines in terms of all investigated factors (infection, hospitalization, ICU admission, and mortality) has been shown in several studies [57,58,59]. Given the higher COVID-19 complications in OUD cases, preventive measures such as vaccination should be especially considered in them in order to reduce the COVID-19 burden in this highly susceptible population. This is of more importance as there has been a report that complacency and convenience were the main barriers to COVID-19 vaccination in people with OUD [60].

Study strengths and limitations

This study provided evidence for evaluating associations between OUD and COVID-19 outcomes. Several studies evaluated the effects of SUDs on COVID-19 outcomes; nevertheless, OUD has been less addressed individually in the literature. The low number of included articles, therefore, constituted a limitation of the present study. Given the several low-quality articles or those with a small sample, the evidence obtained for COVID-19 outcomes was of low certainty. Moreover, the observational nature of studies and the potential risk of confounding biases, in addition to the low number of studies for some of the outcomes, could have an impact on the overall pooled result. Further evidence is therefore required for determining the accuracy and generalizability of the present findings, especially ICU admission, based on relevant factors and comorbidities. Importantly, this study focuses on the early phase of the COVID-19 pandemic and, therefore, may have been affected during the next phases and introduction of vaccines. In many countries, it can be applicable and provide valuable information regarding OUD and COVID-19. The diverse definitions provided for OUD also decreased the number of included articles; nevertheless, efforts were made to uniformly define OUD in the present study, especially in the context of pandemics.


Our meta-analysis revealed that OUD was not associated with COVID-19 infection; however, patients with OUD were more likely to be hospitalized and receive treatment in ICU. Moreover, according to the meta-analysis, mortality was reported to be higher in the patients with OUD compared to the other patients. Therefore, as this population is at higher risk of suffering and complications from the COVID-19 pandemic, policymakers and healthcare systems should pay special attention to them.

Availability of data and materials

Not applicable.



Coronavirus disease-2019


Opioid use disorder


Severe acute respiratory syndrome coronavirus 2


Substance use disorder


Intensive care unit


Newcastle–Ottawa Scale


Polymerase chain reaction


Preferred reporting items for systematic reviews and meta-analyses


  1. WHO. Listings of WHO’s response to COVID-19 2020.

  2. WHO. WHO coronavirus (COVID-19) dashboard.

  3. Behnoush AH, Ahmadi N, Mozafar M, Mirghaderi SP, Azad AJ, Houjaghan AK, et al. Anxiety, depression, and their contributing factors among nurses infected with COVID-19 in Iran: a cross-sectional study. Iranian Red Crescent Med J. 2022;24(2).

  4. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study. Lancet. 2020;395(10239):1763–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bandyopadhyay S, Baticulon RE, Kadhum M, Alser M, Ojuka DK, Badereddin Y, et al. Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review. BMJ Global Health. 2020;5(12):e003097.

    Article  PubMed  Google Scholar 

  6. Shali M, Behnoush AH, Shabani EA, Khazaeipour Z. Individual and working experiences of healthcare workers infected with COVID-19 A qualitative study. Japan J Nursing Sci. 2022;19(2):12465.

    Article  Google Scholar 

  7. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018 392(10159):1789–858.

  8. Schimmel J, Manini AF. Opioid use disorder and COVID-19: biological plausibility for worsened outcomes. Subst Use Misuse. 2020;55(11):1900–1.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Mansuri Z, Shah B, Trivedi C, Beg U, Patel H, Jolly T. Opioid use disorder treatment and potential interactions with novel COVID-19 medications: a clinical perspective. Primary Care Companion CNS Dis. 2020;22(4):27062.

    Google Scholar 

  10. Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. 2020;173(1):57–8.

    Article  PubMed  Google Scholar 

  11. Becker WC, Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020;173(1):59–60.

    Article  PubMed  Google Scholar 

  12. Qeadan F, Mensah NA, Tingey B, Bern R, Rees T, Madden EF, et al. The association between opioids, environmental, demographic, and socioeconomic indicators and COVID-19 mortality rates in the United States: an ecological study at the county level. Archiv Public Health. 2021;79(1):101.

    Article  Google Scholar 

  13. Fond G, Pauly V, Leone M, Llorca PM, Orleans V, Loundou A, et al. Disparities in intensive care unit admission and mortality among patients with Schizophrenia and COVID-19: a national cohort study. Schizophr Bull. 2021;47(3):624–34.

    Article  PubMed  Google Scholar 

  14. Jeon HL, Kwon JS, Park SH, Shin JY. Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study. Br J psychiatry J Mental Sci. 2021;218(6):344–51.

    Article  Google Scholar 

  15. Wei Y, Shah R. Substance use disorder in the COVID-19 pandemic a systematic review of vulnerabilities and complications. Pharmaceuticals. 2020;13(7):155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kumar N, Janmohamed K, Nyhan K, Martins SS, Cerda M, Hasin D, et al. Substance use and substance use disorder, in relation to COVID-19: protocol for a scoping review. Syst Rev. 2021;10(1):48.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535.

    Article  PubMed  PubMed Central  Google Scholar 

  18. GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000

  19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

    Article  CAS  PubMed  Google Scholar 

  21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Baillargeon J, Polychronopoulou E, Kuo YF, Raji MA. The Impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv. 2021;72(5):578–81.

    Article  PubMed  Google Scholar 

  23. Velásquez García HA, Wilton J, Smolina K, Chong M, Rasali D, Otterstatter M, et al. Mental health and substance use associated with hospitalization among people with COVID-19: a population-based cohort study. Viruses. 2021;13(11):2196.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Vallecillo G, Perelló R, Güerri R, Fonseca F, Torrens M. Clinical impact of COVID-19 on people with substance use disorders. J Public Health. 2021;43(1):9–12.

    Article  CAS  Google Scholar 

  25. Allen B, El Shahawy O, Rogers ES, Hochman S, Khan MR, Krawczyk N. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York city: january-october 2020. J Public Health (Oxf). 2021;43(3):462–5.

    Article  PubMed  Google Scholar 

  26. Qeadan F, Tingey B, Bern R, Porucznik CA, English K, Saeed AI, et al. Opioid use disorder and health service utilization among COVID-19 patients in the US: a nationwide cohort from the cerner real-world data. EClinicalMedicine. 2021;37: 100938.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–9.

    Article  CAS  PubMed  Google Scholar 

  28. Jamali Z, Emamian MH, Hashemi H, Fotouh A. The association of opioid use disorder and COVID-19 in shahroud Iran. medrxiv. 2021;02(19):21252093.

    Google Scholar 

  29. Riahi T, Sadeghzadeh-Bazargan A, Shokri S, Ahmadvand D, Hassanlouei B, Baghestani A, et al. The effect of opium on severity of COVID-19 infection: an original study from Iran. Med J Islam Repub Iran. 2021;35:115.

    PubMed  PubMed Central  Google Scholar 

  30. Joseph DPR, Krovvidi H. Non-respiratory functions of the lung. Contin Educ Anaesth Crit Care Pain. 2013;13(3):98–102.

    Article  Google Scholar 

  31. Eisenstein TK. The role of opioid receptors in immune system function. Front Immunol. 2019;10:2904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Plein LM, Rittner HL. Opioids and the immune system—friend or foe. Br J Pharmacol. 2018;175(14):2717–25.

    Article  CAS  PubMed  Google Scholar 

  33. Farhoudian A, Baldacchino A, Clark N, Gerra G, Ekhtiari H, Dom G, et al. COVID-19 and substance use disorders: recommendations to a comprehensive healthcare response an international society of addiction medicine practice and policy interest group position paper. Basic Clin Neurosci. 2020;11(2):133–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Saeedi M, Omrani-Nava V, Maleki I, Hedayatizadeh-Omran A, Ahmadi A, Moosazadeh M, et al. Opium addiction and COVID-19: truth or false beliefs. Iran J Psychiatry Behav Sci. 2020;14(2):103509.

    Article  Google Scholar 

  35. Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173(1):61–2.

    Article  PubMed  Google Scholar 

  36. Melamed OC, Hauck TS, Buckley L, Selby P, Mulsant BH. COVID-19 and persons with substance use disorders: Inequities and mitigation strategies. Subst abuse. 2020;41(3):286–91.

    Article  Google Scholar 

  37. de Bernardis E, Busà L. A putative role for the tobacco mosaic virus in smokers’ resistance to COVID-19. Med Hypotheses. 2020;143: 110153.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Mhatre S, Srivastava T, Naik S, Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: a review. Phytomed Int J Phytother Phytopharmacol. 2021;85: 153286.

    CAS  Google Scholar 

  39. Enns A, Pinto A, Venugopal J, Grywacheski V, Gheorghe M, Kakkar T, et al. Substance use and related harms in the context of COVID-19: a conceptual model. Health Promot Chron Dis Prevention Canada Res Policy Pract. 2020;40(11–12):342–9.

    Google Scholar 

  40. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Namba RS, Singh A, Paxton EW, Inacio MCS. Patient factors associated with prolonged postoperative opioid use after total knee arthroplasty. J Arthroplasty. 2018;33(8):2449–54.

    Article  PubMed  Google Scholar 

  42. Kobus AM, Smith DH, Morasco BJ, Johnson ES, Yang X, Petrik AF, et al. Correlates of higher-dose opioid medication use for low back pain in primary care. J Pain. 2012;13(11):1131–8.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Buckeridge D, Huang A, Hanley J, Kelome A, Reidel K, Verma A, et al. Risk of injury associated with opioid use in older adults. J Am Geriatr Soc. 2010;58(9):1664–70.

    Article  PubMed  Google Scholar 

  44. Ataei M, Shirazi FM, Lamarine RJ, Nakhaee S, Mehrpour O. A double-edged sword of using opioids and COVID-19: a toxicological view. Subst Abuse Treat Prev Policy. 2020;15(1):91.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Porubsky S, Kuppe C, Maier T, Birk HW, Wörnle M, Moeller MJ, et al. Renal lipidosis in patients enrolled in a methadone substitution program. Arch Pathol Lab Med. 2014;138(5):689–93.

    Article  PubMed  Google Scholar 

  46. Yamanaka T, Sadikot RT. Opioid effect on lungs. Respirology. 2013;18(2):255–62.

    Article  PubMed  Google Scholar 

  47. Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2011;6(4):442–65.

    Article  Google Scholar 

  48. García-Albéniz X, del Amo J, Polo R, Morales-Asencio JM, Hernán MA. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. Eur J Epidemiol. 2022;37(8):789–96.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Ayerbe L, Risco-Risco C, Forgnone I, Pérez-Piñar M, Ayis S. Azithromycin in patients with COVID-19: a systematic review and meta-analysis. J Antimicrob Chemother. 2022;77(2):303–9.

    Article  CAS  PubMed  Google Scholar 

  50. Chang KC, Huang CL, Liang HY, Chang SS, Wang YC, Liang WM, et al. Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. J Cardiovasc Electrophysiol. 2012;23(5):527–33.

    Article  PubMed  Google Scholar 

  51. Fonseca F, Marti-Almor J, Pastor A, Cladellas M, Farré M, de la Torre R, et al. Prevalence of long QTc interval in methadone maintenance patients. Drug Alcohol Depend. 2009;99(1–3):327–32.

    Article  PubMed  Google Scholar 

  52. Kim L, Garg S, O’Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus Disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis Off publ Infect Dis Soc Am. 2021;72(9):e206–14.

    Article  CAS  Google Scholar 

  53. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York city: prospective cohort study. BMJ. 2020;369: m1966.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Reilev M, Kristensen KB, Pottegård A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49(5):1468–81.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Balaram K, Marwaha R, Kaelber DC. The effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes. Curr Opin Psychiatry. 2021;34(4):386–92.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Schwetz TA, Calder T, Rosenthal E, Kattakuzhy S, Fauci AS. Opioids and infectious diseases: a converging public health crisis. J Infect Dis. 2019;220(3):346–9.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355–71.

    Article  CAS  PubMed  Google Scholar 

  58. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043–54.

    Article  CAS  PubMed  Google Scholar 

  59. Rzymski P, Kasianchuk N, Sikora D, Poniedziałek B. COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022. J Med Virol. 2022.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Vallecillo G, Durán X, Canosa I, Roquer A, Martinez MC, Perelló R. COVID-19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona. Spain Drug Alcohol Rev. 2022;41(6):1311–8.

    Article  PubMed  Google Scholar 

Download references


The authors gratefully acknowledge the Tehran University of Medical Sciences for their guidance.


This research received no specific grant from funding agencies in the public, commercial, or non-profit sectors.

Author information

Authors and Affiliations



BB and EB contributed to the search, while AHB and MF screened them. EB and BB extracted the data from studies, and AHB meta-analyzed the extracted data. Finally, EB and AHB contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Behnam Behnoush.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing of interests

The authors reported no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Keywords used for search in databases. Table S2. Newcastle Ottawa Scale for Quality Assessment. Figure S1. Results of COVID-19 hospitalization outcome meta-analysis. Figure S2. Results of COVID-19 ICU admission outcome meta-analysis. Figure S3. Results of COVID-19 mortality outcome meta-analysis. Figure S4. Bubble plot of meta-regression of sample size. Figure S5. Bubble plot of meta-regression of NOS score. Figure S6. Bubble plot of meta-regression of publication year. Figure S7. Bubble plot of meta-regression of male percentage. Figure S8. Funnel plot for COVID-19 infection in patients with OUD.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Behnoush, A.H., Bazmi, E., Forouzesh, M. et al. Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis. Addict Sci Clin Pract 17, 68 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: